2006, Number 1
PDF size: 84.27 Kb.
ABSTRACTObjective: To report the experience in the management of rectal cancer.
Setting: Third level health care hospital.
Statistical analysis: Percentages as summary measure for qualitative variables, chi square test for proportions, Pearson’s X2, and Fisher’s and Yate’s exact probability test.
Design: Retrospective, transversal, observational, descriptive study.
Patients and methods: We analyzed the patients with cancer of the rectum. The analyzed variables were gender, age, schooling, residence place, main symptoms, cabinet studies, and clinical staging. Besides, we compared the results of treatment with and without neoadjuvants.
Results: We studies 43 men and 54 women with rectal cancer, average age was 49.9 years; schooling level was 30% illiterate and 46% primary school. The main symptom was hematochezia, average evolution time of 10 months. Location of the tumor was: upper third, 7%; mid third, 30%; and lower third, 60%. Three patients were in clinical stage I, 15 in stage II, 52 in stage III, and 27 in stage IV. Four patients were treated only with surgery and became disease-free; 32 patients were subjected to surgery with adjuvant chemo and radiotherapy, of these, 7 presented local recurrence. In 21 patients, neoadjuvant chemo and radiotherapies were used besides surgery and adjuvant chemo and radiotherapy, 4 of them presented local recurrence. Recurrence frequency was lower in clinical stage II with neoadjuvants. General mortality was of 52%.
Conclusion: Rectal cancer is a disease with predominance in women. Level of schooling is no prognostic factor. The search for rectal cancer must start at the age of 30 years. In patients coursing with hematochezia, rectal cancer must be excluded. Treatment even in early stages must be with neoadjuvant therapy.
Becouarn Y, Blanc-Vincent MP, Ducreux M, Lasser P, Dubois JB, Giovannini M, et al. Cancer of the rectum. Br J Cancer 2001; 84 Suppl 2: 69-73.
Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96.
Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44: 52-8.
Miles WE. A meted of performing abdominoperineal excision of the rectum and of the terminal portion of the pelvic colon. Lancet 1908; 2: 1812-13.
Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 1996; 78: 968-76.
Petrelli NJ, Nagel S, Rodriguez-Bigas M, Piedmonte M, Herrera L. Morbidity and mortality following abdominoperineal resection for rectal adenocarcinoma. Am Surg 1993; 59: 400-4.
Williams JT, Slack WW. A prospective study of sexual function after major colorectal surgery. Br J Surg 1980; 67: 772-4.
Zaheer S, Pemberton JH, Farouk R, Dozois RR, Wolff BG, Ilstrup D. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998; 227: 800-11.
Tjandra JJ, Kilkenny JW, Buie WD, Hyman N, Simmang C, Anthony T, et al. Practice parameters for the management of rectal cancer (Revised). Dis Colon Rectum 2005; 48: 411-423.
MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-60.
Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer 2005; 115: 148-54.
Heald RJ, Ryall R. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1(8496): 1479-82.
Tovar-Guzmán V, Flores-Aldana M, Salmerón-Castro J, Lozcano-Ponce EC. Epidemiologic panorama of colorectal cancer in México, 1980-1993. Dis Colon Rectum 1998; 41: 225-31.